BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10604968)

  • 1. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
    Lim HJ; Masin D; Madden TD; Bally MB
    J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.
    Lim HJ; Parr MJ; Masin D; McIntosh NL; Madden TD; Zhang G; Johnstone S; Bally MB
    Clin Cancer Res; 2000 Nov; 6(11):4449-60. PubMed ID: 11106266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
    Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
    Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
    Genne P; Olsson NO; Gutierrez G; Duchamp O; Chauffert B
    Anticancer Drug Des; 1994 Apr; 9(2):73-84. PubMed ID: 8166930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
    Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
    Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
    Mayer LD; Dougherty G; Harasym TO; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.
    Cui J; Li C; Wang L; Wang C; Yang H; Li Y; Zhang L; Zhang L; Guo W; Liang M
    Int J Pharm; 2009 Feb; 368(1-2):24-30. PubMed ID: 18973800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal drugs dispersed in hydrogels. Effect of liposome, drug and gel properties on drug release kinetics.
    Mourtas S; Fotopoulou S; Duraj S; Sfika V; Tsakiroglou C; Antimisiaris SG
    Colloids Surf B Biointerfaces; 2007 Apr; 55(2):212-21. PubMed ID: 17223020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
    Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
    Harasym TO; Cullis PR; Bally MB
    Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
    Li C; Cui J; Wang C; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
    Int J Pharm; 2008 Oct; 362(1-2):60-6. PubMed ID: 18598745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
    Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
    Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.